Manhattan Scientifics executed an agreement to collaborate with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a breakthrough technology developed by Edward R. Flynn, PhD, for the very early detection of cancer. Dr. Flynn is the founder and chief scientist of MHTX’s subsidiary, Senior Scientific LLC.
Responsive holograms that change colour in the presence of certain compounds are being developed into portable medical tests and devices, which could be used to monitor conditions such as diabetes, cardiac function, infections, electrolyte or hormone imbalance easily and inexpensively.
Rice University scientists have created a way to fine-tune a process critical to the pharmaceutical industry that could save a lot of time and money.
Findings from a Loyola University Medical Center study ultimately could lead to tests to screen for and diagnose bladder cancer.
Cour Pharmaceutical Development Company, Inc., a biopharmaceutical company, announced today the publication of new data in Science Translational Medicine that shows the potential of its proprietary therapy, known as Immune Modifying Nanoparticles (IMP), to reduce inflammation and promote tissue repair and regeneration in patients who have suffered a heart attack. More than 750,000 patients suffer from heart attacks & related complications each year.
Up to 30 percent of heart attack patients suffer a new heart attack because cardiologists are unable to control inflammation inside heart arteries — the process that leads to clots rupturing and causing myocardial infarction or stroke.
A team of researchers led by an NIBIB grantee at Vanderbilt University has created a biodegradable scaffold that enables sustained, local delivery of gene-silencing factors called siRNA to promote tissue regeneration.
After a heart attack, much of the damage to the heart muscle is caused by inflammatory cells that rush to the scene of the oxygen-starved tissue. But that inflammatory damage is slashed in half when microparticles are injected into the blood stream within 24 hours of the attack, according to new preclinical research from Northwestern Medicine® and the University of Sydney in Australia.
Researchers at the Nanoscience Center (NSC) of University of Jyväskylä in Finland have developed a novel method to study enterovirus structures and their functions. The method will help to obtain new information on trafficking of viruses in cells and tissues as well as on the mechanisms of virus opening inside cells. This new information is important for example for developing new antiviral drugs and vaccines.
As if being sick weren't bad enough, there's also the fear of frequent injections, side effects and overdosing on you medication. Now a team of researchers from University of Copenhagen, Department of Chemistry, Nano- science center and the Institut Laue-Langevin (ILL), have shown that reservoirs of anti-viral pharmaceuticals could be manufactured to bind specifically to infected tissue such as cancer cells for the slow concentrated delivery of drug treatments.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.